TGTX

TG Therapeutics Inc

65.76

Nov 11 • 3:59 PM ET +1.50 (2.33%)

65.79

Aftermarket • 4:48 PM ET +0.03 (0.05%)

Healthcare Biotechnology USA Mid NASD

Nov 09, 6:33 PMTG Therapeutics beats Q3 estimates and raises 2026 guidance as BRIUMVI tops $1B annualized U.S. run-rate

Peers: BIIB IMUX NVS AXSM ARGX CTNM ACAD CABA KYTX SNY

| Held by: IJR VTI IWM XBI VB FBT VBK VXF IWO SPSM

Scroll to Statements

Index	RUT
Market Cap	9.94B
Enterprise Value	10.19B
Income	106.06M
Sales	897.76M
Book/sh	3.78
Cash/sh	3.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	399
IPO	Dec 14, 1995

P/E	97.67
Forward P/E	23.30
PEG	2.02
P/S	11.07
P/B	17.37
P/C	19.70
P/FCF	116.17
EV/EBITDA	52.61
EV/Sales	11.35
Quick Ratio	3.75
Current Ratio	4.50
Debt/Eq	1.32
LT Debt/Eq	1.32
Option/Short	Yes / Yes

EPS (ttm)	0.67
EPS next Y	2.82
EPS next Q	0.52
EPS this Y	-62.66%
EPS next Y	172.89%
EPS next 5Y	11.54%
EPS past 3/5Y	- -
Sales past 3/5Y	504.86% 426.73%
EPS Y/Y TTM	-75.71%
Sales Y/Y TTM	68.78%
EPS Q/Q	-85.35%
Sales Q/Q	60.74%
Earnings	Nov 09 BMO
EPS/Sales Surpr.	-2.59% 5.89%

Insider Own	7.47%
Insider Trans	-0.04%
Inst Own	74.24%
Inst Trans	3.31%
ROA	8.10%
ROE	17.99%
ROIC	8.01%
Gross Margin	82.74%
Oper. Margin	21.48%
Profit Margin	11.81%
SMA20	13.40%
SMA50	16.63%
SMA200	46.02%
Trades

Shs Outstand	151.16M
Shs Float	141.64M
Short Float	20.31%
Short Ratio	15.06
Short Interest	28.77M
52W High	68.03 -3.34%
52W Low	26.76 145.74%
Volatility	8.46% 5.39%
ATR (14)	3.26
RSI (14)	69.78
Beta	1.80
Rel Volume	1.08
Avg Volume	1.91M
Volume	2,057,565

Perf Week	6.70%
Perf Month	21.02%
Perf Quarter	37.17%
Perf Half Y	54.19%
Perf YTD	120.60%
Perf Year	111.38%
Perf 3Y	543.44%
Perf 5Y	98.25%
Perf 10Y	1074.29%
Recom	1.33
Target Price	69.43
Prev Close	64.26
Price	65.76
Change %	2.33%

Consensus

Strong Buy

Avg. Price Target

$69.43

Implied Upside

+5.6%

Analysts11incl. previous ratings

Rating Distribution9 Buy · 1 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 06, 2025	Resumed	HH.C. Wainwright	Buy	$60	-8.8%
Jul 10, 2025	Resumed	GGoldman	Neutral	$37	-43.7%
Oct 29, 2024	Initiated	TTD Cowen	Buy	$50	-24.0%
Aug 02, 2023	Upgrade	GGoldman	Sell → Neutral	$16 → $12	-81.8%
Jun 26, 2023	Resumed	JJefferies	Buy	$55 → $40	-39.2%
May 20, 2022	Initiated	BBofA Securities	Underperform	$5	-92.4%
Feb 23, 2022	Reiterated	RB. Riley Securities	Buy	$49 → $35	-46.8%
Nov 15, 2021	Downgrade	GGoldman	Neutral → Sell	$33 → $26	-60.5%
Apr 20, 2021	Initiated	GGoldman	Neutral	$50	-24.0%
Apr 19, 2021	Reiterated	HH.C. Wainwright	Buy	$79 → $89	+35.3%
Sep 01, 2020	Initiated	JJP Morgan	Overweight	$38	-42.2%
Aug 11, 2020	Reiterated	HH.C. Wainwright	Buy	$32 → $38	-42.2%
Jun 05, 2020	Initiated	EEvercore ISI	Outperform	$60	-8.8%
Jan 17, 2020	Reiterated	HH.C. Wainwright	Buy	$20 → $24	-63.5%
Nov 27, 2019	Resumed	BB. Riley FBR	Buy	$12	-81.8%
Feb 06, 2019	Resumed	JJefferies	Buy	$8	-87.8%
Sep 25, 2018	Downgrade	RRaymond James	Strong Buy → Outperform
Mar 09, 2018	Reiterated	BB. Riley FBR, Inc.	Buy	$21.50 → $27	-58.9%
Dec 01, 2017	Resumed	BB. Riley FBR, Inc.	Buy	$21.50	-67.3%
Nov 14, 2017	Resumed	HH.C. Wainwright	Buy	$33	-49.8%

Nov-10-26 12:59PM	How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, Novartis (Investor's Business Daily)
Nov-09-26 10:49AM	TG Therapeutics Misses The Whisper But Raises Guidance A Fourth Time, Leaving More Of The Year Riding On Q4 (Earnings Whispers) +5.94%
08:26AM	TG Therapeutics CEO Sees Global Revenue Exceeding $1B In 2026 BRIUMVI Drives Q3 Topline Beat (Stocktwits)
07:11AM	TG Therapeutics: Q3 Earnings Snapshot (Associated Press)
06:00AM	TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance (Business Wire)
08:16PM	Loading…
Nov-08-26 08:16PM	Biotech Beats SPY And QQQ In Market Rout Now Hims Earnings And Summits FDA Test Take Center Stage (Stocktwits)
Nov-02-26 04:15PM	TG Therapeutics Tests Briumvi Momentum Against Seasonal Lull As Stock Nears Breakout (Earnings Whispers)
06:30AM	TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update (Business Wire)
Oct-31-26 08:06AM	EBay Leads Five Stocks Near Buy Points From Resilient Sectors (Investor's Business Daily)
Oct-30-26 02:00PM	TGTX Stock Hits Fresh 52-Week High Ahead Of Earnings Amid Buyout Buzz (Stocktwits) +5.34%
Oct-23-26 02:07PM	TGTX Stock Bucks Broader Biotech Selloff As Multiple Sclerosis Therapy Shows Promising Early Results Heres What Investors Need To Know (Stocktwits)
10:55AM	TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 (Business Wire)
Oct-21-26 08:52AM	TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026 (Business Wire)
Oct-18-26 11:15PM	Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In (Stocktwits)
Oct-12-26 07:30AM	TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis (Business Wire)
07:30AM	Loading…
Oct-08-26 07:30AM	TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 (Business Wire)
Sep-22-26 11:14PM	Dow Jones Futures: Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals (Investor's Business Daily)
Sep-17-26 08:21AM	Dow Jones Futures Rise After Hawkish Fed, Warsh Hit Stocks, Trump Fumes; AMD, Bloom Energy Eye Buy Points (Investor's Business Daily)
Sep-16-26 04:03PM	TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry (Investor's Business Daily) +5.30%
Sep-10-26 07:30AM	TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Sep-03-26 07:30AM	TG Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-02-26 12:22PM	IBD Stock Of The Day, TG Therapeutics, Eyes Breakout After Topping Early Buy Point (Investor's Business Daily)
Sep-01-26 03:27PM	TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis (Stocktwits)
Aug-24-26 12:57PM	TGTX Stock Outperforms 95% of Stocks. Here's Why. (Investor's Business Daily)
Aug-21-26 03:54PM	TGTX Stock On Track For Best Day In 3.5 Months Amid Fresh Buyout Rumors (Stocktwits) +7.34%
Aug-06-26 07:01AM	Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Aug-03-26 09:38AM	Why This Top-Notch Trio Of Biotech Stocks Just Took A Tumble (Investor's Business Daily) -11.26%
08:42AM	TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug Retail Shrugs Off EPS Miss (Stocktwits)
08:20AM	TG Therapeutics Raises 2026 Outlook Following Strong Briumvi Sales Growth (InvestorsHub)
07:08AM	TG Therapeutics: Q2 Earnings Snapshot (Associated Press)
07:00AM	Loading…
07:00AM	TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance (GlobeNewswire)
Jul-29-26 07:30AM	TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update (GlobeNewswire)
Jul-24-26 01:31PM	How Roche Unexpectedly Buoyed IBD Stock Of The Day TG Therapeutics (Investor's Business Daily)
Jul-07-26 04:13PM	TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch (Stocktwits)
Jul-06-26 07:30AM	TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia (GlobeNewswire)
Jun-18-26 04:15PM	TG Therapeutics Stock Is On A Hot Streak: Why It's Up 79% And Climbing (Investor's Business Daily)
Jun-17-26 05:26PM	TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data (Stocktwits)
Jun-11-26 03:56PM	Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates (Exec Edge)
Jun-10-26 05:00PM	Why This IBD Stock Of The Day, A Roche Rival, Just Broke Out To A Four-Year High (Investor's Business Daily) +7.49%
Jun-09-26 05:03PM	Dow Jones Futures: Market Whipsaws On AI Fears, Trump's Iran Comments; CPI Inflation On Tap (Investor's Business Daily) +5.91%
04:34PM	TGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle Disease (Stocktwits)
07:30AM	TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial (GlobeNewswire)
Jun-03-26 04:48PM	TG Therapeutics Flashes An Early Buy Signal - What Drove The Bullish Jump (Investor's Business Daily) +9.47%
12:43PM	TGTX Stock Applies Brakes On 5-Session Losing Streak Retail Eyes Multi-Billion Sales As At-Home Multiple Sclerosis Treatment Gets Boost (Stocktwits)
07:30AM	TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI (ublituximab-xiiy) (GlobeNewswire)
Jun-02-26 07:30AM	TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference (GlobeNewswire)
Jun-01-26 07:30AM	TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology (GlobeNewswire)
May-28-26 07:30AM	TG Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-27-26 07:30AM	TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial (GlobeNewswire)
May-26-26 07:30AM	TG Therapeutics Announces Data Presentations for BRIUMVI at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting (GlobeNewswire)
May-21-26 12:24PM	Multiple Sclerosis-Focused Biotech Quadruples Its Profit, Raises Sales Forecast (Investor's Business Daily)
May-11-26 02:00PM	Historic Signal Says This Biotech Outperforms (Schaeffer's Research)
May-06-26 07:21AM	TG Therapeutics: Q1 Earnings Snapshot (Associated Press) +16.26%
07:00AM	TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance (GlobeNewswire)
May-05-26 07:01AM	Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Apr-30-26 07:30AM	TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update (GlobeNewswire)
Apr-22-26 07:30AM	TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting (GlobeNewswire) +5.60%
Apr-16-26 05:52AM	TG Therapeutics concludes enrolment in Phase III Briumvi trial (Clinical Trials Arena)
Apr-15-26 07:30AM	TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI (GlobeNewswire)
Mar-19-26 07:30AM	TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million (GlobeNewswire)
Mar-12-26 07:00AM	Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update (Business Wire)
Mar-10-26 08:03AM	BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) (Insider Monkey)
Mar-09-26 07:30AM	Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI in People with Highly Active Relapsing Multiple Sclerosis (GlobeNewswire)
Mar-08-26 06:25AM	Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings (Insider Monkey)
Mar-06-26 07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting (GlobeNewswire)
Mar-02-26 07:01AM	Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis (Business Wire)
Mar-01-26 04:27AM	TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 (Insider Monkey)
Feb-27-26 12:08PM	TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line (Zacks)
08:45AM	TG Therapeutics Q4 Earnings Call Highlights (MarketBeat)
Feb-26-26 04:11PM	TG Therapeutics Inc (TGTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
09:55AM	TG Therapeutics (TGTX) Misses Q4 Earnings Estimates (Zacks)
07:12AM	TG Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance (GlobeNewswire)
Feb-25-26 12:15PM	Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-23-26 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
07:30AM	TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update (GlobeNewswire)
Feb-17-26 07:30AM	Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis (GlobeNewswire)
Feb-11-26 03:14PM	Goldman Sachs Raises TG Therapeutics, Inc. (TGTX) Target to $39 on 2026 Guidance (Insider Monkey)
Feb-08-26 04:17PM	TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis (GlobeNewswire)
Feb-07-26 03:33AM	TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan (Insider Monkey)
Feb-06-26 07:30AM	TG Therapeutics Announces Presentation of Data for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum (GlobeNewswire)
Jan-27-26 07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum (GlobeNewswire)
Jan-15-26 10:31AM	These under-the-radar stocks combine fast growth with big upside potential (MarketWatch)
Jan-14-26 04:39PM	Stock Indexes Settle Lower on Tech Weakness (Barchart) +5.99%
10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
09:45AM	Stocks to Watch Wednesday: Netflix, Bank of America, Wells Fargo (The Wall Street Journal)
09:25AM	Why TG Therapeutics Stock Is Moving Today (Benzinga)
05:03AM	Stock Market Today: Dow Jones, Nasdaq 100 Futures Tumble Ahead Of Supreme Court Ruling On Trump's Tariffs-Wells Fargo, BP, WeRide In Focus (Benzinga)
Jan-13-26 05:05PM	TG Therapeutics Stock Climbs After The Bell: Here's Why (Benzinga)
04:25PM	TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones (GlobeNewswire)
Jan-07-26 07:30AM	TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-25 08:32AM	Is the Options Market Predicting a Spike in TG Therapeutics Stock? (Zacks)
Nov-28-25 07:30AM	TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-19-25 08:30AM	TG Therapeutics Makes 2025 Deloitte Technology Fast 500 List of America's Fastest-Growing Companies (GlobeNewswire)
Nov-10-25 04:00PM	TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit (GlobeNewswire) -6.02%
12:01PM	TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results (Investor's Business Daily)
Nov-05-25 09:45AM	Why TG Therapeutics (TGTX) is a Top Growth Stock for the Long-Term (Zacks)
Nov-04-25 10:26AM	TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised (Zacks)
Nov-03-25 04:25PM	Highly Watched TG Therapeutics Smashes Profit Views But There's A Caveat (Investor's Business Daily)
04:00PM	TG Therapeutics Inc (TGTX) Q3 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ... (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Charney Laurence N	Director	Sep 10 '26	Sale	54.96	5,000	274,800	168,640	Sep 14 05:00 PM
Charney Laurence N	Director	Sep 10 '26	Proposed Sale	54.96	5,000	274,794		Sep 10 04:46 PM
Echelard Yann	Director	Nov 24 '25	Sale	32.57	5,000	162,850	223,816	Nov 25 05:31 PM
Echelard Yann	Director	Nov 24 '25	Proposed Sale	32.57	5,000	162,850		Nov 24 04:04 PM

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

J.D.Mr. Michael S. Weiss Esq.

CFOMr. Sean A. Power CPA

Senior Vice President of Corporate CommunicationsMs. Jenna Bosco

Chief Commercialization OfficerMr. Adam Waldman

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

TGTX

TG Therapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.